Evidence map›Paper›PMID 42755578›Full record

ArticleFrontiers in immunology2026

Xingyu Liu, Shuhan Li, Weijia Chen, Jie Wang, Qiuju Liu, Feiyu Fu, Qi Shao, Zhaofei Wang, Jingjiao Ma, Hengan Wang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xingyu LiuShanghai Key Laboratory of Veterinary Biotechnology, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, China.
Shuhan LiShanghai Key Laboratory of Veterinary Biotechnology, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, China.
Weijia ChenShanghai Jiao Tong University School of Medicine, Shanghai, China.
Jie WangShanghai Key Laboratory of Veterinary Biotechnology, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, China.
Qiuju LiuShanghai Key Laboratory of Veterinary Biotechnology, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, China.
Feiyu FuShanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.
Qi ShaoShanghai Key Laboratory of Veterinary Biotechnology, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, China.
Zhaofei WangShanghai Key Laboratory of Veterinary Biotechnology, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, China.
Jingjiao MaShanghai Key Laboratory of Veterinary Biotechnology, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, China.
Hengan WangShanghai Key Laboratory of Veterinary Biotechnology, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, China.
Yaxian YanShanghai Key Laboratory of Veterinary Biotechnology, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, China.
Yuqiang ChengShanghai Key Laboratory of Veterinary Biotechnology, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, China.
Jianhe SunShanghai Key Laboratory of Veterinary Biotechnology, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Bats display diverse antiviral responses, but interferon-β remains poorly characterized in many bat species. Here, we characterized interferon-β from Methods: TBIFN-β was analyzed by comparative sequence analysis and homology modeling. TBIFNB promoter fragments were evaluated using dual-luciferase assays following batIRF1 expression or poly(I:C) treatment. Antiviral activity was assessed using VSV-GFP and VACV-GFP infection models, together with viral transcript quantification by RT-qPCR. Downstream signaling was examined through interferon-stimulated gene expression, Pyridone 6-mediated JAK inhibition, conditioned-medium stimulation, STAT1 phosphorylation, and exploratory RNA sequencing followed by GO/KEGG enrichment analysis and RT-qPCR validation. Results: TBIFN-β retained the principal predicted structural features of mammalian type I interferons. VSV-GFP and VACV-GFP infection induced distinct temporal changes in endogenous TBIFNB and interferon-stimulated gene expression. Both -900/0 and -500/0 TBIFNB promoter fragments responded to batIRF1 and poly(I:C). Transfection with the TBIFN-β expression construct reduced VSV-GFP and VACV-GFP fluorescence and decreased VSV-NP and VACV-C23L transcript copy equivalents. TBIFN-β induced context-dependent expression of PKR, OAS1, and Mx-1, with OAS1 showing the most consistent response. Pyridone 6 attenuated TBIFN-β-associated STAT1 and ISG responses and partially reduced its antiviral effects. Conditioned medium containing Flag-tagged TBIFN-β induced Pyridone 6-sensitive STAT1 phosphorylation in recipient cells. Transcriptomic analysis further revealed coordinated interferon-associated and antiviral transcriptional responses following TBIFN-β overexpression. Discussion: These findings provide an integrated

Indexed as

ChiropteraInterferon-betaJanus KinasesPromoter Regions, GeneticAnimalsAntiviral AgentsCell LineSignal TransductionSTAT1 Transcription FactorTranscription, GeneticAntiviral AgentsInterferon-betaJanus KinasesSTAT1 Transcription Factorantiviral activityinnate immunityinterferon-βpromoterTadarida brasiliensis

Identifiers

PMID42755578
PMCPMC13581577

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.